Moreover, it is increasingly recognized that cancer survivors have a distinct physiological and cellular environment, characterized by chronic inflammation and alterations in hormone receptor expression due to cancer treatments, which may further influence their response to HRT [50,52]. The gene discussed is NR4A1; the disease is cancer.